American Society of Retina Specialists

Thomas Ciulla speaks about the “real-world” outcomes for anti-VEGF therapy in patients with diabetic macular edema (DME) in the United States.

The device uses an efficient, user-friendly, smart algorithm to measure contrast function.

Sirolimus plus aflibercept showed marked reduction in intraretinal and subretinal fluid compared with aflibercept alone for patients with wet AMD.

Rajeev Muni speaks about the 1-year results of a randomized trial comparing Pneumatic Retinopexy vs. Vitrectomy in the management of primary Rhegmatogenous Retinal Detachment.

The drug is being tested as a potential nAMD combination therapy with ranibizumab.

In an analysis of dosing subgroups through 96 weeks of the VIEW 1 and 2 trials, aflibercept injections showed similar results in meeting visual acuity endpoints to ranibizumab.

ICON-1 plus ranibizumab effectively reduced CNV size and led to complete drying of the retina for some patients with wet AMD.

Pravin Dugel, MD, talks about the study results for OPT-302 and the possibilities that further data could provide for DME, nAMD, and diabetic retinopathy.

Patients taking 440µg doses of the drug saw better results than those treated with 44µg doses

Intravitreal bevacizumab effectively lowered the risk of retinal detachment recurrence after primary pars plana vitrectomy.

Patients experienced prolonged time to treatment failure, meeting primary endpoints in VISUAL I and II trials.

Improvements in visual acuity were less pronounced in the "real-world" setting compared with randomized trials for diabetic macular edema.

Jeffrey Luttrull, MD, speaks about the reduced risk of choroidal neovascularization following use of the subthreshold diode micropulse laser (SDM) retinal protective therapy™ (RPT) for patients with Dry AMD.

Jeffrey Heier talks about RGX-314 gene therapy and the advantages of subretinal delivery.

Patients treated with C3F8 saw a superlative 84% release rate, according to study authors.

RGX-314 could help to alleviate the overall treatment burden for patients with wet age-related macular degeneration via a one-time subretinal injection.

While Anti-VEGF medications can be an effective treatment for patients with diabetic macular edema many will not respond to it making steroids the preferred method for care.

With medical equipment being universal in operating rooms everywhere having the tools personalized for surgeons could be somewhat of an uphill battle depending on how popular the idea becomes.

While surgeons across the globe have become used to performing procedures with the same equipment as their colleagues there could be some benefit to having tools specifically designed for their individual preferences.

In an age where personalization is a key selling point for many items research is being done as to whether this could apply to equipment eye surgeons use in the operating room.

For patients with retinitis pigmentosa the loss of vision can be a difficult consequence of the condition. An implanted device may not give them back the sight they once had but it can provide a chance to see the world around them in a new way.

Doctors treating patients with age-related macular degeneration face a wide range of complications including the potential dosage for anti-VEGF medications. One question is what role these drugs play in macular atrophy.

As technology improves across the medical spectrum new devices, including implants, are providing help for patients who just a few years ago may not have had any treatment options available.

Researchers set out to see how prevalent sleep problems are in people with age-related macular degeneration (AMD) at the 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS 2016) in San Francisco, California.

A team from Philadelphia set out to uncover visual outcomes associated with switching to aflibercept from bevacizumab or ranibizumab.

Researchers from three institutions in Illinois collaborated to examine real world visual outcomes for people with wet age-related macular degeneration (AMD) on anti-vascular endothelial growth factor (VEGF) drugs.

In a poster presentation at the 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS 2016) in San Francisco, California, researchers looked at how patients responded to telemedicine in ophthalmology.

Despite established criteria for patients at risk for vision-threatening diabetic retinopathy from the United Kingdom Prospective Diabetes Study (UKPDS), referral rates don’t reflect the number of people who should visit optometrists, ophthalmologists, and retina specialists.

It’s been unclear whether statins affect the development of diabetic microvascular complications, therefore, Alam Park, MD, from the Ajou University School of Medicine in Korea, and colleagues set out to uncover just that.

Suleyman Kaynak, MD, and colleagues from the Dokuz Eylul University in Turkey, evaluated an alternative therapy for patients who do not respond well to intravitreal ranibizumab.